Stuart Lemarr

At Alkermes, we apply our deep neuroscience expertise to develop medicines designed to help people living with complex and difficult-to-treat psychiatric and neurological disorders, including addiction, serious mental illness and sleep disorders. With our portfolio of marketed medicines and investigational pipeline candidates, we seek to make a meaningful difference the way people manage these chronic diseases. Our patient-inspired science, integrated research strategy, sophisticated development capabilities and specialized commercial infrastructure enable us to pursue the development and commercialization of innovative new medicines, including those for people with conditions that have traditionally been overlooked or stigmatized. Our greatest strengths at Alkermes are our people and our inherent empathy for patients, families and caregivers. Neurological and psychiatric disorders strike people at the core of who they are and impact many facets of their lives. We work with urgency to develop new treatment options for people living with these conditions. Our core values also guide and define our culture and contribute to our recognition as an employer of choice in the biotech industry. In 2025, Alkermes was proud to be recognized as: - A Best Workplace in BioTech and Pharmaceuticals by Fortune Magazine; - A Top Place to Work in Massachusetts by the Boston Globe; - A Best Place to Work in Ireland by the Sunday Times Ireland; and - A Best Place to Work in Greater Cincinnati by the Cincinnati Business Courier Alkermes is headquartered in Ireland, and also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. See our Community Guidelines: https://www.alkermes.com/social-community-guidelines